Athenex, Inc.
DelistedCIK 1300699fmd_0CGMNGYF2N9AKP7S4M4BG5RMBWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2022, 29 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 14 | 21 | 38 | 89 | 101 | 144 | 95 | 103 |
| Cost of revenue | 13 | 20 | 25 | 47 | 70 | 95 | 63 | 76 |
| Net interest income | – | (2) | (6) | (2) | – | – | – | – |
| Gross profit | 1 | 1 | 13 | 42 | 32 | 49 | 32 | 27 |
| Research and development | 24 | 61 | 77 | 120 | 84 | 76 | 78 | 52 |
| Selling, general and administrative | 27 | 26 | 46 | 49 | 66 | 93 | 64 | 45 |
| Total operating expenses | – | – | – | 169 | 151 | 169 | 183 | 97 |
| Operating income | (51) | (86) | (110) | (127) | (119) | (120) | (150) | (70) |
| Interest expense | 0 | 2 | 6 | 4 | 7 | 11 | 21 | 26 |
| Interest and investment income | – | – | 0 | 2 | 2 | 1 | 0 | 0 |
| Income before taxes | (51) | (88) | (131) | (129) | (124) | (140) | (171) | (99) |
| Income tax expense | (0) | (0) | 0 | 0 | 1 | 4 | (11) | 0 |
| Net income from continuing operations | (51) | (88) | (131) | (129) | (125) | (144) | (160) | (99) |
| Net income | (51) | (88) | (131) | (117) | (124) | (146) | (200) | (103) |